In this study, we explored the telomeric changes that occur in B-Chronic Lymphocytic Leukemia (B-CLL), in which telomere length has recently been demonstrated to be a powerful prognostic marker. We carried out a transcriptomic analysis of telomerase components (hTERT and Dyskerin), shelterin proteins (TRF1, TRF2, hRAP1, TIN2, POT1
Introduction
Telomeres are nucleoprotein structures that cap chromosomes and shorten with each division.
Telomere structure and functions depend on the telomerase enzyme (hTERT, hTR, Dyskerin) for elongation 1 , on the shelterin complex (TRF1, TRF2, TIN2, hRAP1, TPP1, POT1) that regulates telomere length and protects them against degradation and fusion and on a set of multifunctional factors including RPA1, hEST1A, Ku70/Ku80 and the RAD50-MRE11-NBS1 complex 2 ( Figure 1A ).
Telomerase activity is absent or very low in somatic cells and increased in proliferative lymphoid cells 3 . In most cancer cells, the catalytic subunit of telomerase (hTERT) is overexpressed to allow their long term proliferation 4 . Researche in oncogenesis is now focusing on the other telomeric genes, especially the shelterin complex [5] [6] [7] [8] [9] [10] . Specific changes in the expression of these genes in cancers may provide new knowledge about oncogenesis and useful clinical markers, but would also lead to the development of new therapeutic agents.
B-Cell Chronic Lymphocytic Leukemia (B-CLL), results from the progressive accumulation of a leukemic clone (for review see 11 ), that show lower telomerase activity at disease onset 12 and increased activity in advanced stages and bad prognosis group 13 . Telomeres are shorter in B-CLL cells versus normal B cells, and especially short for patients with bad prognosis.
Telomere length is thus a powerful prognostic marker for B-CLL 13, 14 . In this work, we investigated whether the transcriptional status of the telomeric proteins is modified in B-cells from B-CLL patients.
For personal use only. on July 14, 2017. by guest www.bloodjournal.org From
Materials and Methods

Isolation of human B cells
After consent and according to institutional guidelines, total blood samples were collected from 20 healthy donors (at the "Etablissement Français du Sang" of Lyon and Pitié-Salpétrière Hospital) and from 42 B-CLL patients (at the Lyon Sud and Pitié-Salpétrière Hospitals). Diagnoses were confirmed using morphology and flow-cytometry usual B-CLL characteristics (Matutes score 
Statistical analysis
Gene expression levels were normalized using three reference genes (RPL13A, β-actin and RPL19). Distribution and variance equality were analyzed for each gene, in normal and B-CLL populations. Three different tests were run : Student (for gaussian populations with equal variance), Welch (for gaussian populations with different variance) or Wilcoxon (for non gaussian populations with equal variance) to determine the p-value.
Results and discussion.
We determined the mRNA level of telomeric proteins in B cells from 42 B-CLL patients and 20 healthy donors. As previously published, ZAP-70 and BCL2 expressions were increased and those of Ki67 and hTERT were decreased (respective ratios : 25.6, 21, 0.26 and 0.04) 12, [16] [17] [18] (Figure 1B , E). We further showed that levels of hTERT and telomerase activity are correlated in B cells from one patient and one healthy donor ( Figure 1C-D) . Both levels can not be increased by mitogenic stimulation in the patient cells, in which no cycling activity was observed (data not shown). Among the other factors implicated in telomerase activity, the expression of Dyskerin, POT1 and hEST1A is also significantly reduced (2.4, 5.8 and 4.8 fold, respectively), while the one of TPP1 is increased (5.1 fold). Concerning the other shelterin components, the mRNA levels are lower in B-CLL cells for TRF1 and hRAP1 (2.9 and 3.0 fold, respectively), slightly reduced for TRF2 (1.2 fold) and almost unchanged for TIN2. We also observed a decrease in mRNA level of Ku80, Mre11 and Rad50 (2.1, 2.4 and 11.1 fold respectively) ( Figure 1B ,E) and an increase in RPA1 (9.7 fold).
Although these changes have to be confirmed at the protein level, they are expected to greatly affect the function of telomeres in B-CLL cells. The lower expression level of various factors involved in telomerase activity should impair telomere regeneration at each S-phase.
Moreover, the altered expression of telomere capping factors might disrupt the capping complex, facilitating telomere degradation and shortening independently of the telomerase status. This correlates with telomeric damages already observed in B-CLL cells 11, 19 . Our results, together with the fact that these cells could proliferate at appreciable levels 13 . Finally, our results suggest that B-CLL cells may be particularly sensitive to telomere-damaging drugs, such as BIBR32 that exerts a cytotoxic effect on B-CLL cells mainly by damaging telomeres 22 .
In conclusion, our results provide the first evidence of a global modification in the expression of telomeric genes in B-CLL, which is characterized by a low expression of many components involved in telomere elongation and capping. 
FISH analyses were led to determine 13q14, 17p13, 11q22 deletion and trisomy 12 (+12). ND : Not Done, NA : Not Available, N : Normal + : previously treated, M : Mutated, UM : Unmutated, add : addition, del : deletion, t : translocation.
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